Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Think we need to send an email to Faz asking him what’s going on.
Plenty of CEO respond to individual investor emails. He should be no different.
Can’t forget that possibly the main reason for not selling the product was due to lack of iOS mobile app.
They stated in the conference that they were working on getting this finished. The way Faz spoke about it seemed like he didn’t realize at the time that Android and Apple software don’t speak to each other.
Also not sure how you can read into this. I used to work for a 16mil/year, small company and was discussing sugarbeat to the big boss. He told me that he had invested in Nemaura Pharma as part of his share portfolio.
Meant garmin
My understanding is that open sourced is allowing 3rd party companies to use the source code to allow them to incorporate into their own software.
For instance, Harmon may decide to use the data and incorporate into their watch. This bypasses having to go to mobile phone.
Sending data to the cloud is only a means of storing data and uploading onto a device.
The way this is written is terrible.
Feels like they've quickly written it out and pressed the send button.
Very disappointed.
Did anyone attend/view the seminar?
https://www.easd-industry.com/programme/industry-symposium-nemaura-medical-inc
Dexcom and Abbot presenting on Monday
Just had the call, was pretty difficult to hear at times during it as one person had a TV switched on throughout the call.
I only managed to ask 2 questions right at the end cause had trouble un-muting the phone.
Faz started the call by giving a quick overview of SugarBeat, benefits, marketing and plans for Europe.
Key Points
Transmitter - Will last for 3 years
Daily Disposable - Same manufacturing process as other daily disposables
So the parts are minimal cost
Marketing - 2 Prong Approach
They are speaking with several companies regarding collaboration with SugarBeat. These companies have significant access to a captive audience. Faz said they are in discussion with several such partners.
Also, the NHS is actively funding. They are interested in anything to do with diabetes prevention and reversal. SugarBeat is ideally positioned.
So they are in discussion with number of parties in UK who have substantial presence in Diabetes market.
DallasBurston - Will offer various subscription based models on their website which will be ready for next quarter. This is for consumers to access directly and self fund.
Faz described Dallas as having an impeccable record of bringing products to enormous success.
Next month they will be presenting in front of several thousand experts in diabetes.
So NMRD want to establish and build a robust presence in the UK. They will then push into Germany, France, Italy, Spain... then Mid East...
Apparently they have only received the branding/literature. Alot of the electronic parts are on a 30/40week lead time and this is one of reasons why they placed the initial order last year.
FDA. They expect to have communciation back in 3months time from submission. We are in week 5 already.
The transmitter is single (bluetooth) communication but can be used on multiple apps.
Someone brought up about how much NHS pays per month? Finger Prick Testing is £40/45 and is funder, Abbott is Double this..
If think of anything else will let you know.
Conference call is tomorrow. For those that will not be able to dial in, do you want to share what questions you would like asked?
We could draw up a list and just keep check that they have been asked.
Maybe Nemaura will get the date wrong on that one, but will work in our favour this time!
Finally....
So does anyone know what the timeline would be for an expedited review? Key global companies sounds interesting..
I think this is a game changer really.
The next step for running watches is to be able to accurately monitor your glucose readings. Can also monitor lactic acid which is a big plus.
This isn't possible with DexCom/Abbot as the user would have to keep this on for a number of days and costs would spiral.
I can see how big companies like garmin/sunto would be able to offer this as an add on. Perhaps they would brand the patch themselves?
So this reads to me that worst case scenario that brexit goes through with no deal we will still be able to get CE Approval
I sent another message which was more clearer. This is a reply from BDI chat
If a company is in the process of awaiting CE Approval But then Brexit happens and we leave the EU on the 29th March. Will that company ever receive CE Approval?
A. If the manufacturer has an application with BSI then we will transfer the data to our Netherlands notified body. The Netherlands NB can accept the evidence as historic data, complete the required tasks and deliver the required certificate.
Are medical devices still covered by CE Certificate?
This UK company received CE Approval 2 weeks ago.
https://www.medilinkem.com/surepulse-vs-achieves-ce-approval/
I've been doing a little digging on google 'CE Approval Brexit' and it appears that medical devices will continue to use the CE Approval
Link from Feb 2019
https://www.lexology.com/library/detail.aspx?g=a2a0485a-3bfc-44f5-8ae5-73400deb8e9a
Where did you read about the stockholders meeting?
Where did you find that message?
Doesn't look likely that a CE Approval will happen in January now
Also when (if) it does go through I'll send out a couple of sensors to US :)
So I'm just having a look to see where I could buy the FreeStyle Libre and the Dexcom in the UK just now.
I would've thought that they could sell both devices in the largest pharmacies in the UK (Boots / Lloyds). I can only see test strips for the Libre on the Lloyds website (prescription only).
This site is selling the Abbott Libre - 'Chemist 4 U'
Abbott Libre Chemist 4 U
The most expensive product for Glucose Monitoring is this one... Which is pretty pricey for what it is.
Expensive Glucose - Boots
Interestingly, upon going on the FreeStyle Libre UK Website, An alert box is shown as soon as I go on...
Yeah I'll be buying one when it hits shelf. I can't wait to try this
Nemaura reduces warm up (calibration) time by half. Gone from 1hr to 30mins
http://nemauramedical.com/nemaura-medical-announces-improvement-to-sugarbeat-continuous-glucose-monitor/
Apple going into Diabetes management? A light emitting sensor sounds pretty unique... No idea how far away that tech is though.
“Apple has shown great interest in diabetes, and the continuous glucose monitoring concept,” says Creative Strategies president and long-time Apple analyst Tim Bajarin. Bajarin, who is diabetic, uses a system from Dexcom, which monitors blood sugar via a couple of small prongs that penetrate just beneath the wearer’s skin at the abdomen, and derives a measurement by sampling the glucose present in the interstitial fluid there. The blood sugar levels are available continuously and are transmitted wirelessly to the Apple Watch display.
Apple has also worked with a company called One Drop, which makes a blood glucose monitoring kit that can send the results of a user’s blood test directly to the Apple Watch.
While Dexcom and One Drop currently rely on directly sampling fluid or blood from the user’s body, Apple is said to be chasing the holy grail of a contactless means of sampling blood sugar levels. The company would like to measure blood sugar levels using a light emitting sensor that could, perhaps, shine light down into the bloodstream in a user’s wrist and identify blood sugar molecules.
“It’s very difficult to do but I know they have great interest in it,” Bajarin told me. If Apple were to find a way to use such an approach to gather reliable results, it could change the lives of a great many people. The American Diabetes Association says roughly 23 million people in the U.S. have diabetes, and another 7 million have it but are undiagnosed. Worldwide, the number of people living with diabetes is well past 400 million.
https://www.fastcompany.com/90292242/apple-will-likely-tackle-these-three-big-healthcare-challenges-next
I was just thinking about this a few days back. This would be another fantastic product
How would you go about purchasing the offering? For some reason I thought this was only available to select few/companies.
Just a case of contacting your broker?
Yeah they are paid advertisements, there is a disclaimer at the bottom of the website.
@BigBill will know better than me as I signed up to the email alerts once Bill mentioned it one here.
I've received most likely 2 paid for stock promotions from AwesomeStocks which has resulted in NMRD releasing news the very next day.
11th September - AwesomeStock e-mail promoting up NMRD
FYI To add the video
This is the link
https://www.youtube.com/watch?time_continue=4&v=-F78pxkM4xE
So we take the part after v=
and add in (without spaces) - (FYI It won't show in preview)
[ yt]-F78pxkM4xE[/ yt]
NMRD Successfully Completes Clinical Studies for FDA De-Novo 510(k) Submission
https://globenewswire.com/news-release/2018/12/04/1661588/0/en/Nemaura-Successfully-Completes-Clinical-Studies-for-SugarBEAT-FDA-De-Novo-510-k-Submission.html
Also has anyone seen this YouTube video????
You get a full look at the app in action, can tailor your activity to running/cycling etc aswell.
Someone mentioned on here before about Nemaura doing advertisement using Awesome Stocks.
They've just sent an email 'NASDAQ Trade Alert'. Doesn't provide any information but at least it is something just stated the last 2 RNS.
Hello!
Today, we have a new NASDAQ trade alert that could provide increased upside potential.
New Trade Alert: Nemaura Medical Inc. (NASDAQ: NMRD)
We first brought NMRD to your attention earlier this year. Following our alert in September, NMRD rallied upwards of 56%.
Over the past few weeks NMRD has consolidated below its 20 and 50 day moving averages.
This once again provides a potentially similar opportunity to the one in September.
In the event that NMRD breaks out above and stays above its 20 and 50 day moving averages, this could present increased upside potential.
NMRD has a 200 day moving average of 2.99, 52% above today’s close.
NMRD is a “medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor.”
NMRD could be one of the few undervalued companies in its sector.
Some of NMRD’s closest competitors in the glucose monitoring sector have been reaching new all-time highs in 2018.
What’s interesting is that NMRD could have a better product than its competitors...
The current leading products in the market are invasive, requiring a needle like sensor to be inserted under the skin.
NMRD’s “patent-protected technology” on the other hand is “non-invasive” using an “adhesive skin-patch connected to a rechargeable transmitter”.
This could potentially be a game changer, and not only for people with diabetes…
According to the company’s website, “BEAT™ technology will allow for remote continuous monitoring of chronic diseases and health conditions”, “allowing both users and healthcare professionals to closely monitor chronic diseases.”
Moreover, since our last alert, NMRD announced that it “Successfully Develops Predictive Algorithms and Alarm Functionality for Continuous Glucose Monitor SugarBEAT®”
“Results indicate the alarm functionality can predict glucose level 5 minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with 90% accuracy.”
“This development is expected to make sugarBEAT® more appealing to insulin users, a Total Addressable Market valued at $50Bn. CGM adoption amongst people with diabetes is minimal and growing rapidly, with the U.S. the largest single market, with an estimated 2.6% (630,000 users) of all diagnosed diabetics using CGM in 2018, representing annualized growth of 117%.”
Here is a summary from NMRD of it’s “Recent Highlights and Accomplishments”:
“SugarBEAT® reported positive interim data from clinic portion of study, planned for FDA submission.”
“Nemaura signed letter of intent for SugarBEAT® commercial launch in Qatar.”
“SugarBEAT® reported positive data for potential zero/reduced frequency of finger stick calibration.”
“Nemaura successfully developed predictive algorithms that will allow alarm functionality for sugarBEAT®.”
Dr. Faz Chowdhury, CEO of Nemaura Medical commented “we have maintained our well capitalised financial position to better support the expected commercial launch of sugarBEAT® in the United Kingdom in the coming weeks. Moreover, we anticipate achieving profitability in a significantly shorter term frame, as compared to other CGM providers, given the research and development costs we have incurred to date have been substantially lower, a trend we are confident will continue as we commercialize sugarBEAT®.”
Not only that, but NMRD recently announced:
Nemaura Signs License and Distribution Agreement for SugarBEAT® Commercial Launch in Qatar
“LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by persons with diabetes and pre-diabetics, today announced that it has signed an exclusive license and distribution agreement with Al-Danah Medical Co. for the commercial launch of sugarBEAT® in Qatar in readiness for 2019 launch.
Qatar, has one of the world’s highest prevalence of diabetes, with 17% of the population diabetic and 23% pre-diabetic(1), and also has the world’s highest GDP per capita, and therefore represents a significant market for sugarBEAT®. Al-Danah Medical Company, part of the Almana Group, is a leading medical product distributor in Qatar, representing multiple global brands.
Current global CGM usage rates are low and growing rapidly. The U.S. is the largest single market, where CGM is being used by an estimated 2.6% (630,000 users) of all diagnosed diabetics in 2018, representing annualised growth of 117%. SugarBEAT® is expected to receive CE Mark approval shortly and launch next month in the United Kingdom, an addresable market for CGM estimated at $1.38B per annum. The global addressable market for CGM is estimated at $82B per annum.(2)”
NMRD presents a potentially compelling trade opportunity, which could continue to attract increased interest from Wall Street as more investors become familiar with the company.
If you agree, don’t miss this opportunity.
Heard this on the radio today
'Wearable glucose monitors will be made available to tens of thousands more people with type 1 diabetes from April 2019, NHS England has announced'
https://www.bbc.co.uk/news/health-46198366
NMRD strengthens manufacturing team
https://hartsburgnews.com/nemaura-medical-strengthens-manufacturing-team-in-preparation-for-sugarbeat-commercial-launch/124987/
New video with Faz on ProActive Investors released today. It's quite good and he discusses the benefits over the Abbott and Dexcom. It's around 15 minutes long.
https://www.proactiveinvestors.co.uk/companies/stocktube/10928/nemaura-medical-targeting-year-end-for-uk-launch-of-its-glucose-monitor-10928.html
He does say early on that he CE Approval is in progress and is expecting a soft launch by end of the year.
Towards the end, (12min:30s) he states that.. he anticipates before the end of the year that we will get CE Approval.
I was hoping he might of said that it could be anytime now. I suspect it is though...
Is this the video that was posted on Red Hot chip companies
That's a great video. Starting to get real now. CE Mark in a couple of weeks!!
ChangeTower has been showing changes every other day. They're continuously changing the text of SugarBeat. Just small changes to text, nothing massive.
They've also started calling it HbA1c instead of A1c. Think both of these mean the same thing though...
To find the changes, I normally click on the image (Three horizontal Lines) to the left of the image of the camera.
Changes below....
FYI, I also emailed the company a while back asking them to clarify Q3 that was raised in a previous post. Got no reply back.
CHANGES
Old Text
Nemaura Medical is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose trending device designed to help persons with diabetes and pre-diabetics to better manage their blood sugar levels by providing an Ambulatory Glucose Profile (AGP) as a superior metric as compared to a HbA1c reading.
New Text
Nemaura Medical is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to provide persons with diabetes and pre-diabetics with an Ambulatory Glucose Profile (AGP) as a superior metric to better manage their glucose levels as compared to an HbA1c reading. Insulin users can adjunctively use sugarBEAT® when calibrated with a finger-stick glucose reading.
Old Text
Moving beyond A1c towards glucose trending
New Text
Move beyond HbA1c
I check this board everyday
Thank you Whisky and Bill for your informative comments. I’m guessing I’m a little younger, I’m not 63 but 87 if know what I mean.
I’ve never heard of the mySugarWatch (understand that it’s this) but didn’t know there was another marketing etc.
There has been a lot of changes on the website. I’ve been following them, got a tracker on the sugarbeat web page to see any changes. Using ChangeTower which is free up to 3/4 pages.
Thanks for sharing this.
Alot of good info specifically the FDA Fast Track. Once the CE Approval comes through you can see how this can progress.
Yeah I’ve been looking at getting some more of these shares. Was close to getting in once the manufacturing order can through. Quite happy about the drop for now, seems to be going down every single day.
There was talk of earlier about FDA if they had started that and I agree with Whisky. They won’t have started the approvals for that.
We were getting emails when they were beginning the clinical trials for CE.
If I can get close to 2 that’s amazing. Considering they were 1.4 for a while on OTC Market
Yeah excellent news. Needed to hear something like this.
I was thinking this aswell...being walked down to get more financial investment.
It is strange how this happens straight after the last news item...
I've been interested in this stock for a while now. Remember when it was stagnant on $1.4 on OTC for ages then exploded up to $8 or something. Volume wasn't even high, it was really low.
I know its not exactly the same but if you look at Dexcom share price and where they are at now.
If the SugarBeat is significantly cheaper (as they say) compared to competitors then it could be a suitable product for the NHS (UK) to get involved in.
You never know NMRD could get involved with an insulin pump company if they get there MARD <10%. Like the partnership of DexCom and Tandem Pumps in 2015. In partnership with the Chinese academy. Alot of positives in this company.
On side not, I actually thought this would be a decent technology for endurance athletes. This could be the next step for running watches. Shove in a CGM into the garmin watch :)
Why do you think that is? Been following this share for a while now. Won't be long before we CE approval.